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The presenilin genes were first identified as the site of missense mutations causing early onset autosomal dominant
familial Alzheimer's disease. Subsequent work has shown that the presenilin proteins are the catalytic subunits of a
hetero-tetrameric complex containing APH1, nicastrin and PEN-2. This complex (variously termed presenilin complex or
gamma-secretase complex) performs an unusual type of proteolysis in which the transmembrane domains of Type I
proteins are cleaved within the hydrophobic compartment of the membrane. This review describes some of the
molecular and structural biology of this unusual enzyme complex. The presenilin complex is a bilobed structure. The head
domain contains the ectodomain of nicastrin. The base domain contains a central cavity with a lateral cleft that likely
provides the route for access of the substrate to the catalytic cavity within the centre of the base domain. There are
reciprocal allosteric interactions between various sites in the complex that affect its function. For instance, binding of
Compound E, a peptidomimetic inhibitor to the PS1 N-terminus, induces significant conformational changes that reduces
substrate binding at the initial substrate docking site, and thus inhibits substrate cleavage. However, there is a reciprocal
allosteric interaction between these sites such that prior binding of the substrate to the initial docking site paradoxically
increases the binding of the Compound E peptidomimetic inhibitor. Such reciprocal interactions are likely to form the
basis of a gating mechanism that underlies access of substrate to the catalytic site. An increasingly detailed understanding
of the structural biology of the presenilin complex is an essential step towards rational design of substrate- and/or
cleavage site-specific modulators of presenilin complex function.
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Gamma-secretase inhibitor compounds, Gamma-secretase modulator compounds, Lateral gateIntroduction
Multiple lines of evidence suggest that the accumulation
and aggregation/oligomerisation of the Aβ peptide plays a
central role in the pathogenesis of Alzheimer’s disease
(AD). Aβ is derived from the amyloid precursor protein
(APP) after sequential cleavage of APP. In the first step
of the amyloidogenic pathway, APP is cleaved by
BACE1 to generate a soluble N-terminal fragment (β-
sAPP) and a membrane-bound C-terminal fragment,
C99. The C-terminal fragment is then cleaved through
its transmembrane domain by the presenilin complex,
thereby generating a series of proteolytic fragments that
include Aβ peptides (released into the lumen) and
amyloid intracellular domain (AICD, released into theCorrespondence: p.hyslop@utoronto.ca
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unless otherwise stated.cytosol) [1-8] (Figure 1). Aβ peptides so produced are of
various lengths and differing abundance, but the principal
species is Aβ40, with lesser amounts of Aβ42. The proteo-
lytic cleavage of the C99 membrane-bound stub begins at
the cytoplasmic face with the initial cleavage, termed ε-
cleavage. The ε-cleavage occurs at residue 49 relative to the
BACE cleavage site, just inside the inner membrane leaflet
[3,5,6,9-11]. A second set of cleavages occur at residue 46,
termed, the ζ-cleavage site [12], producing Aβ46 plus a
small labile C-terminal fragment [3,13,14]. The final cleav-
age occurs at the γ-cleavage site at residue 40, yielding
Aβ40 (Figure 1). However, minor sets of cleavages give rise
to other fragments, for instance Aβ48 (ε), Aβ45 (ζ) and
Aβ42 (γ), which represent products of cleavages on the op-
posite face of the TM helix [11,15-18]. Related ε- and γ-
cleavage sites have been identified during Notch-1 cleavage,
but are named as S3 and S4 cleavages, respectively [19].
Aβ peptides of different length have differing propensities
to aggregate or to cause neurotoxicity [20]. Consequently,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Sequential cleavage sites on APP involved in the β-amyloid producing pathway. Multiple species of Aβ can be produced. The
most prevalent species end at residue 40, but species ending at residue 42, 38 etc. are also generated. Species ending at residue 42 are
particularly prone to oligomerization.
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neurotoxicity could be achieved either by inhibiting total
Aβ production or by modulating the specific Aβ species
produced [21-24]. Recent work with gamma-secretase
modulator (GSM) compounds has highligted the difficulty
in generating substrate-specific inhibitors that potently pre-
vent the generation of amyloidogenic APP cleavage prod-
ucts but exhibit minimal activity toward the cleavage of
other substrates such as Notch-1. Even semi-specific com-
pounds, including semagacestat, inhibit the cleavage of
non-APP target substrates to a degree that causes un-
acceptable side effects [25,26]. This review examines the
function of the presenilin complexes from a structural per-
spective and emphasizes aspects of their biology that will
need to be understood before rational drug design ap-
proaches can be applied to achieve either improved sub-
strate specificity and/or to modulate the species of Aβ
produced.
Presenilin complexes
The presenilin (PS) genes were first identified by this
group during searches for genes responsible for earlyonset familial AD (FAD), [27,28]. There are two prese-
nilin genes in vertebrates: PSEN1 (on chromosome 14,
encodes PS1) and PSEN2 (on chromosome 1, encodes
PS2). Both PS1 and PS2 are ~50 kDa polytopic trans-
membrane proteins that interact with nicastrin, PEN-2
and APH1, to form the biologically active γ-secretase
[29-35] (Figure 2). The assembly of these four compo-
nents to a functional γ-secretase complex is tightly
controlled and gives rise to a 1:1:1:1 heterotetrameric
complex with a mass of 174 kDa, as determined by
SEC-MALS [36]. γ-secretase complexes lacking any of
their subunits are destabilised and degraded [37].
Topology and structure of presenilin 1 complex
components
Presenilin
PS1 (and PS2) are the catalytic subunits of the heterote-
trameric presenilin 1 (or presenilin 2) complexes [29,31]
and are the archetypal members of the GXGD family of
intramembranous aspartyl proteases, which also includes
















Figure 2 Topology view of presenilin 1 complex subunits: presenilin (purple), nicastrin (blue), Aph1 (red) and PEN-2 (orange). The
highly conserved sequence in the catalytic pocket, YD287 and GLGD385 (presenilin 1 numbering), has been specified with stars.
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plexes, the PS1 or PS2 subunits undergo endoproteolytic
cleavage into N- and C-terminal fragments [37,43,44]. For
PS1 the cleavage occurs near residue Met298 (encoded by
Exon9) within a cytoplasmic peptide loop encoded by
Exon 8–10 [45].
Presenilin proteins adopt a membrane topology char-
acterized by nine helical transmembrane (TM) domains.
Once folded, its hydrophilic, flexible N-terminus is lo-
cated in the cytosol. In contrast, its C-terminus is either
embedded within the lumenal face of the lipid bilayer or
protrudes into the lumen or extracellular space [46-49].
Crosslinking experiments using a series of TMD-swap
PS1 mutants revealed that TM2 and TM6 are both in
proximity to TM9 [50]. TM6 and TM7 each contain one
of two aspartyl residues required for catalytic activity
[31]. A solution state NMR structure of the PS1-CTF
domain is available that was generated by using a cell-
free expression system and SDS micelles for embedding
the protein [51] (PDB code 2kr6). This model confirmed
the prediction that TM7, TM8 and TM9 are likely to be
helical and also revealed a small helix within the domain
encoded by Exon 9. However, the results are difficult to
interpret, given the solubilization of the protein frag-
ment in SDS micelles, which may exert different con-
straints on protein folding than the lipid bilayer, and the
absence of PS1-NTF and other presenilin subunits.
More recently, a crystal structure has been reported for a
distant homologue of PS1 from the archaeon Methanocul-
leus marisnigri JR1 (MCMJR1) [52]. Like the human PS1
protein, this archaeal protein adopts a membrane topology
that comprises nine transmembrane segments (TMs) and
cleaves itself into N-terminal (encompassing TMs 1–6) and
C-terminal (encompassing TMs 7–9) fragments, each of
which contains a catalytic aspartate residue. The crystal
structure of MCMJR1 reveals a protein fold in which the
N-terminal domain wraps around the C-terminal domain
positioned in the center of the structure. The two catalyticaspartate residues in the structure are observed not to be in
close enough proximity in order for catalysis to occur. In-
deed, the particular construct used in crystallisation, which
has had a large section of the loop between TM6 and 7
proteolytically removed, is inactive (unpublished observa-
tions). The authors suggest a possible route for substrate
access between TM6, TM7, and TM8. However, in the
structural model presented the route appears to be almost
entirely obstructed.
Nicastrin
Nicastrin was the first subunit of the complex to be cloned
after the presenilins [35]. Nicastrin consists of a trans-
membrane helical domain and an extracellular glycosyl-
ated ectodomain. Nicastrin may be involved in regulating
intracellular protein trafficking of the nascent presenilin
complex during its assembly [53-55] and in binding to the
N-terminus of substrates [56,57]. Nicastrin associates with
the hemicomplex comprising PS1-CTF and APH1 by
binding to the the C-terminus of PS1 [58].
Nicastrin is a type I integral membrane protein and
contains a conserved DYIGS motif that may be involved
in substrate binding. The ectodomain of Nicastrin has
been predicted to adopt an aminopeptidase/transferrin
receptor-like secondary structure [59]. Indeed, due to
considerable sequence similarities between the Nicastrin
ectodomain (NECD) and both the human transferrin
receptor (PDB code 1cx8) and the glutamate carboxyl
peptidase PSMA (PDB code 2xef ), the structure of the
nicastrin ECD could be modelled using the X-ray crystal
structures of these proteins as a template. This structural
homology was recently confirmed in a cryo-EM study
[60] (PDB 4upc) and by crystallography [61] (PDB 4r12).
Prior to the atomic structures of NECD [60,61], other
structural studies had predicted additional structural do-
mains downstream of the DYIGS motif and peptidase-
like domains, near residue 571. This domain was initially
predicted to be homologous to tetratricopeptide repeat
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tide recognition [62]. However, a TPR fold was not
apparent in the atomic structures of NECD, which con-
tained most of this domain [60,61].
The function of the NECD is currently the focus of
some controversy. The NECD carries extensive glycosyl-
ation (potentially 16 sites, with ~36 kDa total mass) and
adopts a thermostable structure [63]. The presence of
non-functional peptidase domain in the NECD, together
with observations that indicate nicastrin detects the
lengths of extracellular N-terminal protrusions of sub-
strate proteins, suggest it may be involved in substrate
selection and acquisition [57]. However, nicastrin is not
essential for γ-secretase activity [64].
PEN-2
PEN-2 and the fourth component of the complex,
APH1, were both identified and cloned by genetic
screens in invertebrates for enhancers and suppressors
of Notch signaling [65] PEN-2 is a 101 residue (12 kDa)
membrane protein with two predicted transmembrane
domains. By introducing N-linked glycosylation sites
into the N- and C-termini or the loop region between
the two putative transmembrane helices of PEN-2, it has
been possible to show that both termini of this protein
are luminal, while the hydrophilic loop is cytosolic [66].
PEN-2 binds to the fourth transmembrane domain of
PS1 [67-69] and helps to stabilise the γ-secretase com-
plex after PS1 endoproteolysis [70]. PEN-2 is also sug-
gested to play an essential but as yet poorly understood
role in the final assembly step and activation of the ma-
ture complex [71].
APH1
Anterior Pharynx Defective 1 (APH1) is a protein of ap-
proximately 308 amino acids in C. elegans and 195–265
residues in mammals [65]. In humans, two paralogous
genes, which map to Chromosomes 1 and 15, encode for
the highly similar gene products APH1A and APH1B,
respectively. A further duplication of the APH1B gene in
mice gave rise to a third APH1 family gene, APH1C. Be-
cause only one copy of any of the available APH1 pro-
teins is incorporated into a given presenilin complex,
two different types of PS1 or PS2 complex are observed
in humans, and three different types of PS1 or PS2 com-
plex exist in mice [72]. The function of APH1 is still not
well established, although it is clear that APH1 is re-
quired for γ-secretase activity. All human and mouse
APH1 paralogs contain a conserved GXXXG motif that
may be involved in interactions with other subunits in
the presenilin complex [73]. The membrane topology of
APH1 has been studied by selective permeabilization of
the plasma membrane and immunofluorescence micros-
copy, which revealed that the protein is a multi-passtransmembrane protein with its C-terminus facing the
cytosol. More detailed glycosylation mutagenesis ex-
periments further revealed APH1 to acquire a seven-
transmembrane topology with its N-terminus, as well as
even-numbered loops, facing the lumen [74]. Several
studies have shown that APH1 and nicastrin form a
stable sub-complex [75,76]. It has been suggested that
the APH1:nicastrin complex forms an initial scaffold
prior to the generation of the full presenilin complex
[7,8,55,77,78]. As the assembly of the presenilin complex
progresses the PS1-CTF subunit joins this initial scaf-
folding complex by an interaction between the extreme
PS1 C-terminus and APH1 [58].Structure of presenilin complex: early globular models
Obtaining both static and dynamic structural models of
the presenilin complex is an important step towards un-
derstanding how the complex works. Electron microscopy-
based structural investigations of the presenilin complexes
are non-routine and difficult due to its low molecular
weight and lack of symmetry. Prior to 2014 [79-82], elec-
tron microscopy reconstruction studies generated a variety
of 3D structure models differing in shape and volume.
None of these were validated using independent biophys-
ical methods. The first of these early models used negative
stain electron microscopy to reveal a flat heart-shaped
model resolved at 48 Å and exhibiting C2 symmetry [82].
The presenilin complex occupied a volume of 560 Å ×
320 Å × 240 Å in this structural model. Afterwards, three
more low resolution structure models were generated by
negative stain or cryo-electron microscopy for PS1 com-
plexes isolated in CHAPSO or digitonin [79-81]. The first
of these was a 20 Å resolution globular structure model
with a 120 Å diameter and a 20–40 Å-wide low density
chamber. The model proposed openings at both the top
and bottom surfaces [80] and attributed a small protrusion
to represent the NECD. This model was then improved to
a 12 Å cryo-electron microscopy model with a globular
structure, dimensions of 80 Å × 90 Å × 85 Å and three
solvent-accessible but non-perforating central cavities in
the membrane-embedded domain [81]. The third globular
model was based on cryo-EM data with 18 Å resolution,
and depicted the presenilin complex with a cup-like shape
and a lateral belt surrounding a water-accessible internal
chamber. Based upon labeling experiments that made use
of a γ-secretase transition state inhibitor coupled to gold
particles, the catalytic site was thought to be located in
this chamber. A structure model of a pre-activation,
PEN-2-free complex was also built in this study. Com-
parisons between the pre-activation model and the
model of the mature complex suggested that PEN-2
binding modifies the architecture of the active site dur-
ing complex maturation [79].
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Early in 2014, a considerable advance in the structural
modeling of the presenilin complex was achieved when
negative stain 3D electron microscopy data were com-
bined with several complementary cross-validating bio-
chemical, pharmacological and biophysical methods
including SEC-MALLS and FRET-FLIM [36]. The study
provided an experimentally-validated structure and gen-
erated the first direct visualization of a structurally dy-
namic presenilin complex. Structures were built at 17 Å
using single particle electron microscopic methods for
both the native human PS1 complex and for the human
PS1 complex following the binding of the non-transition
state peptidomimetic γ-secretase inhibitor Compound
E ((S,S)- 2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-
methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]
diazepin-3-yl)-propionamide, M.W. = 490.5 Da). In con-
trast to the globular shape predictions of earlier models,
this work proposed that presenilin complexes have a
bi-lobed shape, containing a larger base (93 Å × 93 Å ×
60 Å) and a separate, smaller head (65 Å × 60 Å × 55 Å)
(Figure 3A). The orientation of the complex was deter-
mined by immuno-labelling the N-terminus of nicastrin
(residues 168–289), which demonstrated that the nicastrin
ectodomain is located in the head domain of the bi-lobed
complex (Figure 3A). In good agreement with this conclu-
sion, the height of the base domain in this model is ap-
proximately 60 Å, which is sufficient to span the widths of
most cellular membranes (35–40 Å) [83,84] and, thus,
large enough to contain the TM domains of PS1, PEN2,
APH1, and NCT.
In partial agreement with some of the earlier models,












With inhibitor CpdE bound
Figure 3 Bi-lobed models of presenilin 1 complex by electron microscopy
stain EM (EMD-2477). (B) The 4.5 Å model of PS1 complex by cryo-EM (EMD-26
with its non-transition state inhibitor Compound E (CpdE) (EMD-2478). This mbase domain that opens toward the lumenal/extracellular
surface (Figure 3A). Crucially, the base domain contained
a lateral cleft that communicated with the central cavity.
This cleft was suggested to be part of a lateral gate mech-
anism involved in substrate access because it was closed
by binding of Compound E, which blocks substrate bind-
ing to the Initial Substrate Docking site [36].
More recently, considerable advances in cryo-EM tech-
nology, in particular the use of new detectors and image
processing methods, enabled further refinements of this
model by increasing the image resolution to 4.5 Å [60]
(EMD-2677, PDB code 4upc). This higher resolution model
confirmed the bi-lobed shape of human presenilin com-
plexes as their native state (Figures 2B and 3B). Multiple
transmembrane helices were also visible in this new model
but the resolution remained insufficient to assign individual
TMs to specific subunits of the complex (Figure 3B).
Subunit interaction and domain movement in the PS1
complex
Inhibitor-induced conformational change
The presence of certain detergents causes a concentration-
dependent dissociation of the presenilin complex into two
hemi-complexes [36,85,86]. Each hemicomplex contains
one catalytic aspartate of the presenilin protein. One
of the hemi-complexes consists of PS1-NTF and PEN2,
while the other hemi complex consists of nicastrin, APH1
and PS1-CTF (Figure 2). Interestingly, inhibitors, such as
Compound E, can stabilise the PS1 complex and prevent
its detergent-induced dissociation [36]. This result suggests
that inhibitor binding causes a conformational change that
brings the complex components closer together. Such




. (A) The first bi-lobed structure model of PS1 complex, 14.7 using negative
77), confirming its bi-lobed shape. (C) 14.7 Å model of PS1 complex bound
odel revealed a conformational change induced by the inhibitor.
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an overall stabilisation of the complex.
This long-range conformational change in the complex
was confirmed indirectly by in vitro intra-molecular Fluor-
escent Lifetime Imaging Microscopy – Förster Resonance
Energy Transfer methods (FLIM-FRET) in which a donor
GFP tag was added to the N-terminus of PS1-NTF and a
acceptor RFP tag was cloned into the loop at the N-
terminus of PS1-CTF. In the presence of Compound E,
there was a significant change in FRET-FLIM, indicat-
ing that the two γ-secretase hemicomplexes have been
brought closer together by Compound E binding [36].
These indirect experiments were then directly confirmed
by negative stain single particle electron microscopy.
The EM structure model for Compound E-bound PS1
complexes was highly similar to the native complexes with
a bi-lobed overall shape. However, there were several crit-




Figure 4 Structure of presenilin protein homologue, SPP. (A) Crystallo
PyMOL and coloured to emphasize different domains. (B) Rainbow coloure
structure (PDB 4hyc, chain A). The active site (magenta) is buried within a hnon-catalytic site on PS1-NTF, PS1 complexes undergo
several allosteric conformational changes that include: 1)
rotation of the nicastrin-containing head domain; and 2)
compaction of the membrane embedded base domain
with closure of the lateral cleft (Figure 3C) [36].
Reciprocal cross-talk between the initial substrate docking
site and the inhibitor binding site
Excitingly, the Li et al. study also revealed that there are
several reciprocal long range interactions between the ini-
tial substrate docking site at the interface between the
PS1-NTF and PS1-CTF and the Compound E binding site.
Specifically, substrate docking increases inhibitor binding
[36]. Conversely, Compound E binding induced a dose-
dependent reduction in substrate binding.
These observations not only demonstrate that the prese-
nilin complex is structurally dynamic, they show for the
first time that there are important reciprocal long-rangeLumen
Cytosol
graphic tetramer of MCMJR1 (PDB 4hyc). The image is generated by
d (The PyMOL Molecular Graphics System, LLC) MCMJR1 monomer
ydrophilic pocket between TM domains.
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within the complex. These findings shed light on how
non-catalytic site inhibitors might work (namely by allo-
sterically closing the substrate docking site). Importantly,
these findings also provide a testable hypothesis on how a
series of reciprocal allosteric interactions could operate a
lateral gate governing substrate access to the protected
catalytic pocket. Thus, binding of substrate at the initial
docking site might open a translocation pathway to permit
movement of the substrate into the complex. Subsequent
occupancy of sites (e.g. the site of binding by the peptide-
mimetic Compound E inhibitor) in the translocation
pathway might then close the initial docking site, until the
substrate is cleaved. At that point, release of the reaction
products relaxes the closure of the initial docking site and
the enzyme can reconfigure to bind a new substrate mol-
ecule. Such a mechanism would account for the slow pro-
cessivity of presenilin complexes.
Structure of presenilin-like homologues
Signal peptide peptidases (SPP) form a family of intramem-
branous aspartyl proteases homologous to presenilins. The
negative stain EM-based structure of human SPP was
determined at 22 Å resolution [87]. The model revealed
SPP as a slender, bullet-shaped homotetramer. Independ-
ent biochemical studies have also suggested that a homote-
trameric complex may be the functional unit of SPP. The
SPP EM model displayed a central chamber possibly analo-
gous to the central chamber/cleft observed in the preseni-
lin archeal homologues (see next paragraph) [87].
More recently, in 2013, a 3.3 Å crystal structure of the
archeal GXGD presenilin-like aspartyl protease MCMJR1
(also known as mmPSH, PDB code 4hyc, 4hyd and 4hyg)
(Figure 4A) revealed that the active site of MCMJR1 is
buried in a hydrophilic pocket formed by the TM domains
[52] (Figure 4B). A lateral cleft between TM6 (located on
PS1-NTF in PS1) and TM9 (on PS1-CTF in PS1) and a
central channel was proposed as a potential route for sub-
strate access, although closer inspection reveals the cleft
between TM6 and TM9 to be occluded in the crystal
structure [52]. It is unclear whether this is: 1) an artefact
of the mutagenesis required to get the protein to crystal-
lise; 2) a packing artefact during crystallization; or 3) the
correct structure. Whether the substrate accesses via a
route between TM6 and TM9 as suggested by some cross-
linking studies therefore remains unresolved.
Conclusions
The recent structural studies on presenilin complexes
represent a major advance toward the overall objective
of understanding the molecular workings of the com-
plex. The initial controversy surrounding the complex’s
overall shape has been put to an end by the consistent
documentation of a bi-lobed structure in the mostrecent models. This bi-lobed model was carefully vali-
dated by multiple independent methods and has since
been further confirmed by higher resolution cryo-EM
data. The head domain of the bi-lobed shape contains
the NECD, and the base domain contains the transmem-
brane domains of all four subcomponent proteins. The
head domain rotates when Compound E inhibitor is
bound to the complex. In its native state the base do-
main adopts an “open” structure with a central cavity
and lateral cleft opening to the side. Compound E bind-
ing is associated with a “closed” conformation.
The next steps for the field will be to build structural
models of the complex associated with various interaction
partners, inhibitors and modulators. These models will fa-
cilitate a mechanistic understanding of all intramembra-
nous aspartyl proteases. Importantly, by mapping the
binding site of different classes of GSM and GSI com-
pounds, and by the defining the consequent three dimen-
sional structural shifts in the architecture of the complex,
it may be possible to design compounds targeting specific
substrates and/or specific cleavage products.
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